A dispersible fixed-dose combination tablet formulation of abacavir/dolutegravir/lamivudine for the treatment of HIV-1 had higher bioavailability of dolutegravir compared to the nondispersible film-coated tablet.
Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.
Children who are HIV-exposed, but uninfected, demonstrated a higher risk of adverse neurologic events during infancy and early childhood associated with ART exposure in-utero.
A flexible, scalable intervention increases antiretroviral therapy and medication-assisted treatment use while reducing mortality in people who inject drugs.
Antiretroviral therapy initiation within 4 weeks of a cryptococcal meningitis diagnosis in PLWHIV appears to be associated with a higher mortality risk.
Tenofovir diphosphate in dried blood spots was strongly associated with virologic suppression in those living with HIV on TDF-based therapies.
The FDA has approved labeling updates for Genvoya, Stribild and Tybost to include new drug-drug interaction data.
The International Antiviral Society-USA Panel has updated its recommendations for the management and prevention of HIV infection, to reflect the most current data on new treatment regimens and strategies.
Ritonavir-boosted protease inhibitor therapy is associated with worse outcomes, including death, in patients with HIV and heart failure.
ART recommended for almost all HIV-infected; should be initiated as soon as possible post diagnosis.
The SWORD 1 and SWORD 2 trials enrolled 1027 HIV-infected and virologically suppressed adults; both trials had an early (Day 1 to Week 52) and late (Week 52 to Week 148) switch phase.
Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in patients with HIV-1
The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide might provide a safe and efficacious option for ongoing treatment of HIV-1 infection
Immediate and deferred switching from a boosted protease inhibitor to a dolutegravir regimen in HIV + patients is found to be highly efficacious.
Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name drugs are coming off patent. But unique challenges surrounding their use remain.
Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.
The rapidly developing landscape of antiretroviral therapy adherence monitoring has great potential for clinical application, but cost-effectiveness and feasibility studies are needed to define the appropriate roles for these new technologies.
Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.
The Copenhagen Co-morbidity in HIV Infection (COCOMO) study assessed the association between risk factors for cardiovascular disease and HIV infection.
More research is needed to better capture the interplay between prediabetes/diabetes and antiretroviral therapy in people with HIV.
Unhealthy alcohol use does not appear to have a short-term direct biological effect on CD4 cell count.
Polyomavirus JC-DNA assessment in plasma samples might complement progressive multifocal leukoencephalopathy diagnosis, especially when cerebrospinal fluid (CSF) is unavailable or polyomavirus JC-DNA is not detectable in CSF.
Benefits of urine lipoarabinomannan include its rapid point-of-care platform, low cost, and readily accessible sample type.
Mental health at the time of antiretroviral therapy initiation indicates early effect on the HIV care continuum.
Since early ART limits HIV reservoir size and preserves central memory CD4 cells, patients treated from primary HIV infection with low HIV-DNA levels might be good candidates for future HIV cure strategies.
In high-income countries, the need for second-line treatments due to the development of acquired drug resistance will increase only slightly under the new ART initiation guidelines.
In patients living with HIV receiving TDF with a ritonavir-boosted protease inhibitor, the risk of CKD may be increased.
Dr Gianella Weibel talks with Dr Li and Dr Dubé, investigators of a new study from the AIDS Clinical Trials Group, which uses an intensively monitored antiretroviral pause to identify changes in HIV reservoirs after anti-HIV medications are stopped.
Study suggests that early initiation of combination antiretroviral therapy and full viral suppression may preserve long-term brain health.
The GRADE framework recommendations provide guidance for combination treatment regimens based on 2 systemic reviews, patient considerations, fetal outcomes, and practical issues.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Homeopathy No Better Than Placebo for Respiratory Infections in Children
- CDC Director Says Congo Ebola Outbreak May Be Uncontainable
- CDC Updates Recommendations for Hepatitis A Vaccination for International Travel
- Long-Term HIV Pre-Exposure Prophylaxis May Induce Significant Microbiome Shifts
- 10th Child Dies in Adenovirus Outbreak at NJ Facility
- Oral Urinary Tract Infection Treatments
- Treating Pseudomonas aeruginosa Infections: Highlights From IDWeek 2018
- Local Gentamicin Application Ineffective in Treatment of Periprosthetic Joint Infection
- High-Dose Influenza Vaccination May Benefit Transplant Recipients
- Social Medicine: The Effect of Social Media on the Anti-Vaccine Movement
- GERD Diagnosis and Management Guidelines
- Improved Care Needed for People With HIV in Prison and After Release
- Novel Point of Care Respiratory Viral Testing Service Shows Potential
- A New Nucleotide Analog Is Well Tolerated, Efficacious Against HCV Genotype 1-4
- Many Linens Delivered To US Hospitals Contaminated With Mucorales Mold